Randomized, Double-blinded, Placebo Controlled Study to Assess Efficacy of Oral 35 mg Per Week Risedronate in Preventing Bone Loss in Postmenopausal Women With Aromatase Inhibitor Therapy for Breast Cancer. [ESSAI RANDOMISE, EN DOUBLE AVEUGLE CONTRE PLACEBO EVALUANT L'EFFICACITE DU RISEDRONATE ORAL 35 MG PAR SEMAINE DANS LA PREVENTION DE LA PERTE OSSEUSE CHEZ LA FEMME ATTEINTE D'UN CANCER DU SEIN TRAITE PAR INHIBITEURS DE L'AROMATASE]
Phase of Trial: Phase III
Latest Information Update: 01 Oct 2013
At a glance
- Drugs Risedronic acid (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- Acronyms RISAROS
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2013 Status changed from recruiting to active, no longer recruiting., as reported by ClinicalTrials.gov record.
- 10 Jul 2012 New trial record